To continue getting breaking news and the full stories from The Boston Globe, subscribe today.

The Boston Globe

Business

Boston.com

Vertex gets early OK for new drug

Kalydeco to treat certain patients with cystic fibrosis

By Robert Weisman

 |  Globe Staff  

  February 01, 2012

Acting three months before its scheduled decision date, the Food and Drug Administration yesterday approved a drug developed by Vertex Pharmaceuticals Inc. to treat some patients suffering from cystic fibrosis, a rare and often fatal genetic disease. The drug, called Kalydeco, is the second therapy from the Cambridge company to receive the FDA’s blessing in the past eight months. Its first drug, Incivek, was approved in May to combat the hepatitis C virus.

Stay with the story. Get full access to BostonGlobe.com for just 99¢

Unlimited access to BostonGlobe.com for only 99¢ for the first 4 weeks. You can cancel at any time.

  • The FULL story all day: Enjoy all of the high-quality, in-depth journalism in the print edition of the Boston Globe — plus breaking news that's updated 24/7.
  • A truly reader-friendly format: It's online news that looks and reads just like the newspaper — uncluttered, uninterrupted.
  • Breakthrough technology: The responsive design automatically adapts content so it always reads perfectly on the digital device of your choice.
Get started today

Free access for home delivery subscribers.

Just need to link your home delivery account; one easy step.

Link my home delivery account

BostonGlobe.comSubscriber Log In

Contact us for help